<![CDATA[FDA OKs Pembrolizumab/EV Combo in Muscle Invasive Bladder Cancer]]>
Regulatoryapprovedpembrolizumabenfortumab vedotinPositive
AI Analysis
Summary
The FDA approved pembrolizumab in combination with enfortumab vedotin for muscle invasive bladder cancer, supported by positive phase 3 KEYNOTE-B15/EV-304 trial data.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
FDA approved pembrolizumab in combination with enfortumab vedotin for muscle invasive bladder cancer based on phase 3 KEYNOTE-B15/EV-304 trial findings
Importance:9/10
Sentiment:
0.85
FDA approvalpembrolizumabenfortumab vedotinbladder cancerphase 3oncology
Related Companies
Read the original article
Published by Cancer Network on July 10, 2026 2:34 PM